BioGend Therapeutics Co., Ltd. (TPEX:6733)
Taiwan · Delayed Price · Currency is TWD 26.30
-2.60 (-9.00%)
Jul 30, 2026, 12:45 PM CST
BioGend Therapeutics Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 229.81 | 222.34 | 167.65 | 109.91 | 31.45 | 9.27 |
Revenue Growth | 27.98% | 32.62% | 52.53% | 249.51% | 239.26% | 565.40% |
Gross Profit Gross Profit Growth | 163.46 | 160.16 | 130.51 | 89.62 | 22.78 | 3.06 |
Operating Income Operating Income Growth | -89.63 | -110.5 | -122.26 | -176.54 | -219.21 | -164.31 |
Net Income Net Income Growth | -67.11 | -84.61 | -116.47 | -156.33 | -184.46 | -138.49 |
Earnings Per Share EPS Growth | -0.55 | -0.69 | -0.95 | -1.30 | -1.79 | -1.37 |
EPS Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Hong Kong and Chinese Mainland Hong Kong and Chinese Mainland Growth | 2.21 | 2.22 | 1.14 | - | - | - |
Taiwan Taiwan Growth | 226.18 | 218.69 | 161.41 | 73.54 | 31.14 | 8.99 |
Other Other Growth | - | - | 2.5 | 0.1 | 0.3 | - |
Malaysia Malaysia Growth | - | 1.43 | 1.9 | - | - | - |
Japan Japan Growth | - | - | 0.7 | 24.88 | 0.01 | - |
Total Total Growth | 229.81 | 222.34 | 167.65 | 109.91 | 31.45 | 9.27 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 862.3 | 517.9 | 619.02 | 724.27 | 493.4 | 689.28 |
Total Debt Total Debt Growth | 5.71 | 6.58 | 9.43 | 13.09 | 15.77 | 4.42 |
Net Cash (Debt) Net Cash Growth | 856.59 | 511.33 | 609.59 | 711.18 | 477.64 | 684.86 |
Net Cash Growth | 48.50% | -16.12% | -14.28% | 48.90% | -30.26% | 33.49% |
Net Cash Per Share Net Cash Per Share Growth | 6.96 | 4.15 | 4.95 | 5.91 | 4.63 | 6.76 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | -44.76 | -63.66 | -98.91 | -138.72 | -168.78 | -136.8 |
Capital Expenditures CapEx Growth | -1.87 | -1.87 | -0.65 | -26.04 | -18.18 | -0.67 |
Free Cash Flow Free Cash Flow Growth | -46.62 | -65.52 | -99.56 | -164.76 | -186.96 | -137.47 |
Free Cash Flow Growth | - | - | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 71.13% | 72.03% | 77.85% | 81.54% | 72.44% | 33.00% |
Operating Margin | -39.00% | -49.70% | -72.93% | -160.63% | -697.11% | -1772.67% |
Pretax Margin | -36.93% | -46.60% | -76.50% | -153.97% | -680.20% | -1556.45% |
Profit Margin | -29.20% | -38.05% | -69.47% | -142.23% | -586.58% | -1494.07% |
FCF Margin | -20.29% | -29.47% | -59.38% | -149.91% | -594.54% | -1483.13% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PS Ratio | 15.64 | 21.48 | 24.94 | 42.83 | 71.46 | 297.47 |